<section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="kW_p1 s_am s_aG s_a3 s_ak"><div class="kW_Iz s_dU"><a data-test-id="logo" title="Home" class="ak_e2 t_ei t_ez" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="ak_hM t_ei t_ew"><svg class="ak_gz ak_fP ak_hI"><use xlink:href="#logo"></use></svg></span></a></div><header class="rV_Fv t_ei t_el t_es t_ez"><div class="vy_g t_ei t_el t_es s_dS ct_n1" data-test-id="quick-links"><div class="vy_We t_ei t_ek t_eu t_eC s_ct s_bO"><div class="vy_UN s_aC s_ah s_aW"><div class="yk_iV" data-test-id="themes-list"><ul class="yk_mT t_ei"><li class="yk_mU t_ei t_ek s_dI"><a data-test-id="theme-links-item" class="J_0 t_ej t_ek t_ep J_f9 J_fw aW_jl aW_jA aW_jR N_L" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="yk_YG iR_vb">Transcripts</span></span></a></li></ul></div></div></div><div class="vy_Wd t_ei t_ek t_es"></div></div><div class="nf_il t_ei t_es"><h1 class="nf_Y s_dS aW_jt aW_jL aW_jR aW_kE aW_kW aW_k1" data-test-id="post-title">Aeterna Zentaris' (AEZS) CEO Michael Ward on Q3 2017 Results - Earnings Call Transcript</h1></div><div class="mb-18 flex justify-between text-medium-2-r md:mb-16 rV_RN t_ei t_ek" data-test-id="post-page-meta"><div><span class="nf_K7 nf_gW r_5" data-test-id="post-date">Nov. 09, 2017 11:12 AM ET</span><span class="nf_gW r_5" data-test-id="post-primary-tickers"><a class="vC_Wk" href="/symbol/AEZS?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAEZS">Aeterna Zentaris Inc. (AEZS)</a>, <a class="vC_Wk" href="/symbol/AEZS:CA?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAEZS%3ACA">AEZS:CA</a></span></div></div></header><div class="tt_N9 t_ei t_el t_es s_dS" data-test-id="author-brief"><div class="tt_ei t_ei"><a class="tt_Lj sm_Lj" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcset="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"></div></a><div class="tt_Oa t_ei t_ep t_ez s_cs"><a class="tt_Lj sm_Lj tt_Ji aW_jn aW_jB aW_jR s_dE sm_Ji" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="tt_ri t_ei t_eu"><div class="rF_Ru aW_jl aW_jA aW_jQ tt_N8 r_5 aW_jl aW_jA aW_jQ">141.08K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="ll_IU" role="none"><button data-state-text="Following" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR js_FS s_af s_bj s_aG s_a3 pL_F7 t_eE tt_wr s_cf aP_i9" data-test-id="follow-button" type="button"><span class=""><span class="js_FU t_ei t_ep" data-state-placeholder="Following"><span class="js_FV">Follow</span></span></span></button></div></div><div><div class="paywall-full-content ja_f t_ei" data-test-id="article-content"><div class="ja_mg t_eC"><div class="ja_iS ja_E1" data-test-id="content-container"><p>Aeterna Zentaris, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/AEZS?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Aeterna Zentaris Inc.">AEZS</a></span>) Q3 2017 Earnings Conference Call November 9, 2017 8:30 AM ET</p> <p><strong>Executives</strong></p> <p>Michael Ward - CEO</p> <p>Jeff Whitnell - Interim CFO</p> <p>Richard Sachse - CMO and CSO</p> <p><strong>Analysts</strong></p> <p>RK Swayampakula - H.C. Wainwright</p> <p><strong>Operator</strong></p> <p>Greetings and welcome to the Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.</p> <p>It is now my pleasure to introduce your host, Michael Ward, Chief Executive Officer for Aeterna Zentaris. Thank you, Mr. Ward, you may now begin.</p> <p><strong>Michael Ward</strong></p> <p>Thank you. Good morning and welcome everyone. This is Michael Ward, Chief Executive Officer of Aeterna Zentaris. And with me today is Jeff Whitnell, our Interim Chief Financial Officer and Richard Sachse, our Chief Medical Officer and Chief Scientific Officer</p> <p>During this call, we will be making forward-looking statements regarding future events and the performance of the Aeterna Zentaris. The forward-looking statements are subject to risks and uncertainties that could cause actual events and results to differ materially from the forward-looking statements. These risks are described in further detail in the company's press releases and reports filed with the US and Canadian securities regulatory authorities.</p> <p>These forward-looking statements represent the company's judgment as of today, Thursday, November 9, 2017 and the company disclaims any intent or obligation to update these forward-looking statements unless we are required to do so by applicable law or by a securities regulatory authority. However, we may choose to update these statements, if we do so, we will disseminate the updates to the investing public.</p> <p class="iS_EF">We appreciate you joining us this morning, during this call my comments will center around the company's laser focus and preparation for FDA<span class="paywall-full-content invisible"> approval of Macrilen by December 30 of this. Macrilen will be the only the FDA approved drug in the United States for assessing growth hormone deficiency in adults and represents a potential game changer for the endocrinology community and patients given its potential to reduce the burden of testing options<span class="paywall-full-content no-summary-bullets invisible"> currently available.</span></span></p> <p class="paywall-full-content invisible no-summary-bullets">We've made progress building out a stronger management team and adopting a disciplined process for review of plans, resources and opportunities. The addition of Jeff Whitnell who joined us on September 25, 2017 as Interim Financial Officer is testimony to our dedication to improve our team. Mr. Whitnell brings over three decades of experience to the company and is accomplished financial executive. He is highly skilled at building effective financial systems, organizational restructuring and developing solutions leading to financial and operational improvements.</p> <p class="paywall-full-content invisible no-summary-bullets">Since joining the company, Mr. Whitnell has helped create a business model focused on cost containment, zero-based budgeting and preserving cash reserves to prepare for the Macrilen launch, including streamlining our global finance department. Additional strategy is to further maximize the value of intellectual risk capital for Macrilen include adjusting the reduction in forced plan in Germany and retaining key employees who contributed to the development of Macrilen.</p> <p class="paywall-full-content invisible no-summary-bullets">We have also retained Stifel Nicolaus as strategic advisor to our strategic review committee of our Board of Directors. At the executive level, we retained Reilly Connect, a communications firm, bringing in three decades of experience in all aspects of communications and marketing in the health pharmaceutical and health sector to strength our messaging. This has been a quarter of strategic change. We are dedicated to building out accomplished and dedicated team to take this through the approval and commercialization of Macrilen and have made significant strides in this quarter to demonstrate our commitment to better position the company to maximize the value of Macrilen upon its approval.</p> <p class="paywall-full-content invisible no-summary-bullets">I will now turn the discussion over to Jeff who will provide more information about our third quarter financial results.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Jeff Whitnell</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Michael. Good everyone, thank you for joining us. Most of what I'll be covering this morning has been presented in more detail in our consolidated interim financial statements and in the management's discussion and analysis of operations for the third quarter of 2017 which the company filed yesterday. Regarding the income statement, a few comments, revenues for the three months ended September 30, 2017 of $241,000 were essentially flat with the comparative prior year quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">On a year-to-date basis, 2017 revenues of $745,000 were higher than preceding 2016 year-to-date revenues due to nine months of earned sales commissions in 2017 versus four months of earned sales commissions in 2016. Operating expenses for the three months ended September 30, 2017 totaled $7.4 million versus $8 million in the comparative prior year quarter. And on a year-to-date basis September 2017 operating expenses were $20.2 million versus $22.5 million for the comparative 2016 year-to-date period.</p> <p class="paywall-full-content invisible no-summary-bullets">The third quarter 2017 operating expenses included approximately $3.1 million of restructuring charges. These restructuring charges pertain to our facility in Germany and include both severance and owners contract lease charges. Also affecting our operating results for the three months ended September 30, 2017 was a $2.6 million charge attributable to the change in fair value recorded in connection with our warrant liability.</p> <p class="paywall-full-content invisible no-summary-bullets">This non-cash mark to market revaluation reflects the increase of our common share price during the third quarter of 2017. On a year-to-date basis we recognized finance income for our warrant liability of $2.7 million for 2017. This non-cash mark-to-market revaluation reflects the decrease of our common share price from January 1, 2017 through September 30, 2017. We used approximately $5.5 million of cash in operations during the three months ended September 30, 2017 as compared to $5.7 million for the same period in 20165.</p> <p class="paywall-full-content invisible no-summary-bullets">This decrease in cash used in operating activities for the third quarter 2017 was the result of our rigorous cost containment efforts and disciplined spending. As of September 30, 2017, our unrestricted cash reserves are $12.2 million. During the quarter, we also utilized our ATM program which contributed cash of approximately $3.3 million.</p> <p class="paywall-full-content invisible no-summary-bullets">I appreciate your attention and will now turn the discussion back to Michael.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Michael Ward</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Jeff. We will open the conference all for questions. And therefore the discussion over to the operator for instructions on the question-and-answer period Thank you.</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] Our first question comes from the line of Jason Kolbert with Maxim Group.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi, there. [indiscernible] on behalf of Jason Kolbert. I'd like to just ask about the strategy for driving adoption with the planned launch of macro in 2018?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. That's a great question Jason. We have been working months with several outsourced partners. We are working with - from a distribution standpoint we're working with ICS which is a subsidiary of AmerisourceBergen. We are also going to be utilizing the telesales program that they have at AmerisourceBergen. Their sales representatives and their reimbursement team as well. We're also using D2 Pharma as part of our reimbursement strategy because as we know, we - you can launch a drug, but if there isn't reimbursement coverage, the launch will not be a successful as you would otherwise hope to have.</p> <p class="paywall-full-content invisible no-summary-bullets">From the European side, our supply chain is ready to go, we have weekly calls with our supply chain partners. So we still anticipate early February 2018 launch of the product upon giving approvals by the FDA on December 30. We intend to build out own sales force. As I look at the kind of the heat map for pituitary and endocrinology centers. I'd like to have an accomplished sales team situated in those areas where we would see the most use of our product in those centers. So we are in process of looking for a VP of sales to build out a sales team. And our sales team is just going to be focused on where the - where we see growth hormone deficiency centers are located and being prescribed.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So are you planning to increase the sales force now or after approval.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, we had a contract sales organization, we've had I guess have done for several years. That agreement expires today. And rather than renew it, it really wasn't the right group of professionals for us to sell Macrilen, we're looking more for those who have more scientific degrees, those who have been in endocrinology and pituitary centers and worked with endocrinologists. We would rather handle it ourselves rather than the contract that important piece out. We will probably start hiring at the mid December. I know a lot of the large pharma companies are in the midst of restructuring, so we think we have a lot of talent out there to recruit from, but we will review recruiting for the geographies in which we believe the largest usage of Macrilen would initially be used, which would be the pituitary centers and endocrinology centers.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And just one more quick question. Looking forward, what are your plans to expand Macrilen? Are you just going to focus on the US right now? I mean, like other geographies or indications?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">We are engaged in out-licensing for ex-US. So we are only going to be selling in the US. We will look for partners outside the US. Dr. Sachse can talk about what we've recently done. I think it was earlier this week, which would - and Richard, if you wouldn't mind just letting Jason know what filing we just made.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Sachse</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. Thanks. As you know, we had our NDA with FDA on the 30th of June and subsequent to these interactions with the FDA, we engaged into discussions with the European regulatory agencies, had a meeting with our [indiscernible] as well as with the EMA, and both meetings really were very encouraging, leading us in the end to submit our MAA to the EMA, meeting the 6th of November time window. The submission is currently under former validation by the EMA and we hope to lead actually the revenue cycle that will start later this month following a formal validation.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] Our next question comes from the line of RK Swayampakula with H.C. Wainwright.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">RK Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I'm sorry if some of these questions have been asked before, because I just got on the call myself. In terms of the Macrilen application with the FDA, could you please highlight for us what sort of communications you all had with the FDA at this point, especially after filing your response to the CRO?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Surely and RK, I will have Dr. Sachse who has been on the frontlines of those communications. Richard, could you?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Sachse</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, RK for the question. We had submitted our NDA as I just stated on the 30th of June, following intensive discussions with the FDA during a meeting back in March this year, during which we agreed with the FDA on a path forward. Following our submission, FDA communicated with us on the PDUFA date, which is determined for the 13th of December this year. And now the package is under review by FDA. We receive [Technical Difficulty] was critical so far in our opinion. Also, FDA already did some site inspections at some of the clinical sites that were involved in the Phase 3 study and the outcome of all these inspections was very good. We're still looking forward to a site inspection of our own office here in Frankfurt and we have the feeling that the submission is well on track and we are looking forward to a hopeful tool on the 13th of December this year.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">RK Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And in terms of having enough material once you get on launch, I know you talked a little bit from the previous - from Jason's questions on commercialization, but just trying to understand regarding having enough material and what sort of a launch are you kind of expecting, are you planning to start up at really key centers initially and then pushing it across the country? How do you want to progress with this launch?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So, RK, we are going to be focusing on the key teaching hospitals, key pituitary centers that our market researchers identified. We recently have gone out with a kind of a market sizing survey that we had a third-party prepared for us and based upon our own co-promotion deal with the size of the product, we have gathered some entail. So we have identified certain pituitary centers and endocrinology centers where we believe the most use of Macrilen would be prescribed. Those will be where we initially target. If we really want to get early adoption with those, we have a fairly strong relationship and Dr. Sachse can probably attest to that as well, with some of our KOLs who conducted some of our clinical studies.</p> <p class="paywall-full-content invisible no-summary-bullets">So we're hearing very good things from our KOLs on Macrilen once it becomes approved and just kind of weaving all that together, we have a fairly solid plan for launch where we would initially send our reps and then from there, we would go to the community based hospitals, but again with what we've seen, our plan is really in the first year to focus on where the key endocrinologists have their practices and put our sales force and our third-party sales force through AmerisourceBergen and other distributors into those centers to educate them about the approval and use of Macrilen.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">RK Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Great. And one last question for me. Is the management continuing to plan to conduct studies outside of the current indication, like for example, TBI was something which had been flagged and so I'm just trying to figure out if you're continuing to think about it and want to do a study in that indication?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. And I can turn this over to Dr. Sachse because we have both the TBI in our radar as well as pediatric and we've actually had a bit of a head start on what we would do for pediatric in Europe. So, Richard, if you wouldn't mind just elaborating a little bit more.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Sachse</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yeah. RK, as we pointed out previously, TBI is not a separate indication, because what we, our label in the end will state that Macrilen - will hopefully state that Macrilen will be indicated for the evaluation of growth hormone deficiency. And this doesn't rule out a particular cause of growth hormone deficiency. In other words, all of the patients that have TBI do already quality for administration with Macrilen and do already qualify for undergoing the evaluation of the diagnosis with Macrilen.</p> <p class="paywall-full-content invisible no-summary-bullets">In fact, quite a significant number of the patients in our Phase 3 study were patients suffering from a TBI. Nevertheless, we are still in discussion with some of the centers who have a lot of patients in TBI and who aim to study the value of the growth hormone treatment in such patients and obviously for - before treating those patients, they need to be diagnosed and we are currently evaluating to what extent our drug could be used for such diagnosis in larger studies and this would obviously help us in the placement of Macrilen. But never forget the indication will not exclude patients with TBI, it will be rather part of the label.</p> <p class="paywall-full-content invisible no-summary-bullets">For pediatrics, this is certainly something that we want to follow on and that we need to follow on. As we previously alluded to, in order to file a MAA in Europe requires that you have agreed with the EMA on a pediatric development plan. We communicated earlier this year that we have agreed with the European EMA on the pediatric development plan and our plan is to engage into such development as soon as possible, however, we also want to have FDA involved and therefore, our plan is as soon as we have approval for, as we engage in to discussions with FDA on the pediatric development plan and then start it off.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Mr. Ward, there are no further question at this time. I'll turn the floor back to you for any final comments.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Michael Ward</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Thank you, everyone for your continued support and interest in Aeterna Zentaris. I really look forward to updating you again when we discuss full year 2017 results.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="ja_E2" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->AEZS<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/symbol/AEZS"><span class="">analysis and news</span></a></li><li class="ja_E2" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nd_J t_ei t_es aP_i9 paywall-full-content" data-test-id="post-footer"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><button class="uE_BS rI_Rx t_ei t_ek uE_jc" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="uE_fv"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="uE_iM">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="custom-share-button" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="ne_iM s_cs">Share</span></span></span></button><button aria-expanded="false" aria-label="Print options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="print-dropdown" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 14 13" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z"></path></svg><span class="ne_iM s_cs">Print</span></span></span></button><a class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU nd_K0" data-test-id="comment-button" href="/article/4122811-aeterna-zentaris-aezs-ceo-michael-ward-on-q3-2017-results-earnings-call-transcript#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="ne_fv nd_K4"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="ne_iM s_cs">Comment</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="recommended-for-you-card-body"><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4637656-sell-everything">Sell Everything</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4640171-cassava-sciences-unconvincing-open-label-studies-upcoming-phase-3-risky-ad-bet">Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet (SAVA)</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Dhierin Bechai profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/009/932/311/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4634186-grupo-aeroportuario-del-pacfico-remains-buy">Grupo Aeroportuario del Pac√≠fico Remains A Buy</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Dhierin Bechai</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644249-wp-carey-will-still-yield-7-percent-after-dividend-cut">W. P. Carey Stock Will Still Yield 7% After The Dividend Cut (NYSE:WPC)</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Muhammad Umair profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/054/273/395/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643414-stoneco-expect-further-consolidation-amidst-solid-financial-health">StoneCo: Expect Further Consolidation Amidst Solid Financial Health</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Muhammad Umair</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Rida Morwa profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/000/016/392/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4642538-thank-you-federal-reserve-xflt">Thank You, Federal Reserve. I'm Earning Over 15%: XFLT</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Rida Morwa</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Fiorillo profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/012/629/971/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644283-meta-platforms-stock-meltdown-opportunity-q3-2023-earnings-maintain-buy">Meta Platforms Share Meltdown Is An Opportunity</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Steven Fiorillo</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Rida Morwa profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/000/016/392/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643833-the-big-short-eisman-says-buy-bonds-and-old-economy-stocks">'The Big Short' Eisman Says Buy Bonds And 'Old Economy' Stocks</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Rida Morwa</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4628227-there-might-not-be-another-chance-like-this-for-years">There Might Not Be Another Chance Like This For Years</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Cress profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/050/113/560/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4641618-seeking-alpha-vs-motley-fool">Seek Alpha: Don't Be A Fool</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Steven Cress</span></footer></div></div></div></article></div></div></div></div></section><div class="rJ_Ry" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="rJ_p1"><div class="paywall-full-content"><div class="ov_MV t_ei t_ek s_dX" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="ov_Y t_ei t_ek aW_jr aW_jH aW_jQ s_cU s_dA" data-test-id="comments-counter">Comments</h4><div><button aria-expanded="false" aria-label="Sort By" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="sort-comments-button" type="button"><span class="truncate"><span class="rE_Rr t_ei t_ek"><span class="rE_Rs s_c3 aY_lE aW_jm aW_jC aW_jQ">Newest</span><div class="sX_SS rE_fv t_ei t_ek"><span class="rE_Rt"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 rG_Rw s_co" data-test-id="dropdown" type="button"><span class="truncate"><span class="rG_os t_ei t_ek t_ep"><svg class="rG_Rv"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="uK_g qo_g s_dU aP_i9" data-test-id="add-comment-form"><div class="uK_Pt qo_Pt t_ei"><div class="uK_E3 s_c9"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="uK_Pu qo_Pu"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 uK_Pv qo_Pv s_dS s_ah s_aC s_a0 s_bl uv_Vl" contenteditable="true" data-test-id="add-comment-input" placeholder="Be the first to comment" role="textbox" tabindex="0"></div><div class="uK_yi qo_yi t_ei t_ek t_eq"><button disabled="" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR uK_Px qo_Px s_cy" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div></div><div class="wI_iM s_bR aW_jm aW_jB aW_jQ"><span>To report an error in this transcript<!-- -->, <button class="J_0 t_ej t_ek t_ep yl_YH" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$-->